Feedback raising £5.59m to scale Bleepa medical image viewing technology
Feedback is raising £5.59million to develop its Bleepa app, which allows medical staff to view and discuss high quality medical grade images securely on mobile devices.
The Bourn-based medtech company has conditionally raised £5.05 million by placing 505,000,000 new ordinary shares.
And a further 53,994,991 shares are available to qualifying shareholders, which could raise £540,000.
The fundraising is subject to shareholder approval at the company’s general meeting on 1 July 1, with the shares expected to be admitted for trading on AIM on July 3.
CEO Tom Oakley said: “At this key moment for our company we are delighted to have generated the support of some of London’s leading institutional investors for our vision of Bleepa.
“Feedback is now a very different company to the one I joined just over a year ago. We now have a singular focus to deliver an exciting clinical product which leverages the best of our longstanding imaging heritage, repurposed to meet the future challenges of the clinical frontline.
“We have taken Bleepa from concept to fully certified medical device in less than a year and gained traction with two NHS sites. This is a remarkable achievement, but it is only the beginning.
“Having established Bleepa we now have ambitious plans to scale Bleepa and get it out to clinicians across the UK and internationally. This funding will enable us to take Bleepa forward at the pace required and we are excited to get started.
“This funding marks a new start for Feedback, as we pivot away from our heritage product lines towards Bleepa, and at this time the company wants to ensure that we reach out to our many loyal, longstanding shareholders, who have supported the company throughout our journey so far.
“It is our desire to ensure that all shareholders have the opportunity to participate in this fundraise and buy in afresh to the company’s new vision. The board has sought to recognise the extraordinary support and longstanding commitment of our shareholders through provision of an open offer.
“Although this is a large raise relative to our current market capitalisation, the board has worked closely with its broker, Stanford Capital, to minimise dilution for shareholders. A fundraise of this level is both essential to allow us to grow at the pace required but is also a validation and endorsement of the vision and opportunity before us.
“With the support of the City and our shareholders we look forward to taking the company forward into a new phase of opportunity.”
Among those using Bleepa is the Royal Papworth Hospital.
More by this authorPaul Brackley
This website and its associated newspaper are members of the Independent Press Standards Organisation (IPSO)